Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Nearly all gene therapy programs are focused on treating rare diseases caused by a single genetic mutation. Now, a new company, Kriya, has raised $80.5 million in series A funding to develop gene therapies for common diseases, including diabetes. The firm’s three lead therapies will encode insulin growth factor 1 for type 1 diabetes; a glucagon-like peptide 1 receptor agonist for type 2 diabetes and obesity; and insulin and glucokinase for both type 1 and type 2 diabetes. Kriya’s roster includes former leaders of the gene therapy firms AveXis, Roivant Sciences, Sangamo Therapeutics, and Spark Therapeutics.
This article has been sent to the following recipient: